IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 6.5% – Should You Sell?

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) fell 6.5% during mid-day trading on Tuesday. The stock traded as low as $28.93 and last traded at $28.3850. Approximately 59,087 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 1,024,211 shares. The stock had previously closed at $30.36.

IDEAYA Biosciences News Roundup

Here’s some of the latest news about IDYA:

  • Positive Sentiment: IDE849 showed encouraging early results in 2L+ neuroendocrine carcinoma: a 52.6% objective response rate and median progression-free survival of 7.0 months in the reported group. These results support the program’s potential, though they come from an early-stage trial. IDE849 trial data
  • Positive Sentiment: Royal Bank of Canada reaffirmed its “outperform” rating and set a $45 price target, signaling analyst confidence in IDEAYA’s outlook. RBC rating
  • Positive Sentiment: IDEAYA nominated IDE101 as a development candidate, a potential first-in-class treatment targeting CDKN2A-deficient solid tumors. Preclinical activity was reported, and the company is conducting studies intended to support an IND filing in the first half of 2027—an earlier-stage, longer-term pipeline opportunity. IDE101 announcement

Analyst Upgrades and Downgrades

Several research firms have weighed in on IDYA. Royal Bank Of Canada reissued an “outperform” rating and issued a $45.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday. William Blair initiated coverage on IDEAYA Biosciences in a research report on Friday, October 16th. They set an “outperform” rating for the company. Wall Street Zen cut IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Wedbush boosted their price target on shares of IDEAYA Biosciences from $60.00 to $63.00 and gave the stock an “outperform” rating in a report on Wednesday, November 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Thursday, October 15th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $49.55.

View Our Latest Stock Analysis on IDYA

IDEAYA Biosciences Trading Down 8.5%

The company has a market cap of $2.69 billion, a P/E ratio of -6.11 and a beta of 0.08. The business’s fifty day moving average is $35.28 and its 200 day moving average is $33.88.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($0.04). IDEAYA Biosciences had a negative net margin of 1,157.18% and a negative return on equity of 39.78%. The firm had revenue of $10.24 million for the quarter, compared to the consensus estimate of $7.58 million. During the same period last year, the company posted $1.33 earnings per share. IDEAYA Biosciences’s revenue for the quarter was up 14.6% on a year-over-year basis. As a group, research analysts expect that IDEAYA Biosciences, Inc. will post -4.63 EPS for the current fiscal year.

Insider Activity

In other news, CEO Yujiro Hata sold 26,338 shares of the company’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total transaction of $985,304.58. Following the transaction, the chief executive officer owned 690,695 shares of the company’s stock, valued at $25,838,899.95. This represents a 3.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IDYA. Aquatic Capital Management LLC raised its stake in IDEAYA Biosciences by 3,154.0% in the 3rd quarter. Aquatic Capital Management LLC now owns 45,361 shares of the company’s stock valued at $1,743,000 after acquiring an additional 43,967 shares during the period. Goldman Sachs Group Inc. boosted its position in IDEAYA Biosciences by 18.1% during the third quarter. Goldman Sachs Group Inc. now owns 1,453,997 shares of the company’s stock worth $55,863,000 after purchasing an additional 222,383 shares during the period. Jump Financial LLC boosted its position in IDEAYA Biosciences by 326.4% during the third quarter. Jump Financial LLC now owns 239,240 shares of the company’s stock worth $9,192,000 after purchasing an additional 183,131 shares during the period. Aberdeen Group plc increased its stake in shares of IDEAYA Biosciences by 5.3% in the third quarter. Aberdeen Group plc now owns 590,777 shares of the company’s stock worth $22,698,000 after purchasing an additional 29,843 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of IDEAYA Biosciences by 96.8% in the third quarter. Russell Investments Group Ltd. now owns 100,855 shares of the company’s stock worth $3,875,000 after purchasing an additional 49,596 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.

Recommended Stories

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.